Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis
Our cohort supports the use of lenvatinib plus pembrolizumab in a real-world population, including CLEAR-ineligible patients. However, AEs should be closely monitored and treatment should be adapted accordingly.
Authors
- Dirk Jäger
- Alexander Cox (ORCID: https://orcid.org/0000-0001-7837-5740)
- Friedemann Zengerling (ORCID: https://orcid.org/0000-0002-6150-2675)
- Christiane Muehle
- Timo Egenolf
- Luka Flegar (ORCID: https://orcid.org/0000-0002-1477-9161)
- Marc Rehlinghaus
- Philipp Ivanyi (ORCID: https://orcid.org/0000-0002-2862-7302)
- Stefanie Zschäbitz (ORCID: https://orcid.org/0000-0001-8917-3263)
- Katrin Schlack (ORCID: https://orcid.org/0000-0001-5843-140X)
- S. Neuberger
- R. Stelmach
- Mathias Reichert (ORCID: https://orcid.org/0000-0003-2045-5005)
- Christopher Darr (ORCID: https://orcid.org/0000-0003-2532-8398)
- Jozefina Casuscelli (ORCID: https://orcid.org/0000-0002-9899-1986)
- Pia Paffenholz (ORCID: https://orcid.org/0000-0002-8209-7795)
- Tim Nestler (ORCID: https://orcid.org/0000-0001-6033-6364)
- Bernhard Brehmer (ORCID: https://orcid.org/0000-0002-5065-7719)
- Manuel Neuberger (ORCID: https://orcid.org/0000-0003-4573-5134)
- V. Grünwald
- Sonia Vallet (ORCID: https://orcid.org/0000-0003-0146-8089)
- S. Erdmann
Institutions
- Philipps University of Marburg (DE)
- University of Cologne (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Bonn (DE)
- University Hospital Heidelberg (DE)
- TUM Klinikum (DE)
- Medizinische Hochschule Hannover (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Zimmer Biomet (Germany) (DE)
- University Hospital Münster (DE)
- National Center for Tumor Diseases (DE)
- Universitätsklinikum Würzburg (DE)
- Evangelisches Diakoniekrankenhaus (DE)
- Karl Landsteiner University of Health Sciences (AT)
- University Hospital Cologne (DE)
- University Hospital Ulm (DE)
- University Medical Centre Mannheim (DE)
- Bundeswehrzentralkrankenhaus Koblenz (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100142
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Merck